Bright Minds Biosciences Receives a Favorable Written Opinion from the International Searching Authority for BMB-202

Press Release

— BMB-202 is a highly selective 5-HT2A agonist that exhibits a more than 30-fold selectivity over 5-HT2C and more than 500-fold selectivity over 5-HT2B – — BMB-202 is the first clinical candidate from an extensive portfolio of selective 5-HT2A and 5-HT2A/2C agonists inspired from natural compound scaffolds –   Vancouver, British Columbia, April 19, 2023…

Bright Minds Biosciences to Present at the 20th International Meeting of the International Society for Serotonin Research

Press Release

— Presentation entitled “BMB-101: A selective 5-HT2C agonist in clinical trials with therapeutic utility” – — First-in-human Phase 1 trial for lead program, BMB-101, is underway in Australia —   Vancouver, British Columbia, April 10, 2023 – Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“Bright Minds” or the “Company”), a biotechnology company focused on developing novel…